Aquestive Therapeutics (AQST) shares ended the last trading session 7.9% higher at $6.69. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 27.1% gain over the past four weeks.The surge in stock price is likely due to positive expectations regarding the company’s key product candidate, Anaphylm, which is currently under review with the FDA for treating severe allergic reactions. Earlier this week, the United States P ...

Shares of Aquestive Therapeutics (NASDAQ:AQST) rose on Wednesday after the company announced that the U.S. regulators had issued two new patents covering its allergy therapy Anaphylm, which is currently under FDA review. The Warren, New Jersey-based biopharma said that the U.S. Patent ...

New patents extend protection for Anaphylm™ into 2037Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe allergic reactions, including anaphylaxis WARREN, N.J., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologi ...

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday.Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA approved PALSONIFY.Also, Baird and JMP Securities raised their respective price targets on the stock.Crinetics Pharmaceuticals shares jumped 23.7% to $44.41 on Friday.Here are some other big stocks recording gains in today’s session.Aquestive Therapeutics, Inc. (NASDAQ: AQST) gained 21.2% to $6.38.Perpetua Resourc ...

文章核心观点 - 多只小盘股在周四盘后交易中出现大幅上涨，主要驱动因素包括公司业务更新、临床进展和战略转型 [1] MEDIROM Healthcare Technologies Inc (MRM) - 公司股价在盘后交易中飙升282.8%至5.55美元，原因是宣布将与Sam Altman等人联合创立的"World"合作，将其生物识别认证设备"Orb"的安装数量翻倍至200家门店 [2] - 该股在常规交易时段收于1.45美元，下跌7.05%，成交量超过3150万股，远高于平均水平，其52周价格区间为0.34美元至5.30美元 [3] Lexaria Bioscience Corp (LEXX) - 公司股价在盘后交易中大涨45.75%至2.23美元，市场重新关注其专利药物递送平台DehydraTECH，该平台已显示出增强GLP-1药物递送的潜力 [4] - 该股在常规交易时段收于1.53美元，上涨7.75%，成交量超过750万股，远高于日均成交量，其52周价格区间为0.775美元至3.392美元 [5] Safety Shot, Inc (SHOT) - 公司股价在盘后交易中上涨12%至0.28美元，原因是宣布与Monarq Asset Management合作，积极管理其BONK持仓国库，这建立在公司近期向数字资产战略转型的基础上 [6] - 该股在常规交易时段收于0.25美元，下跌9.06%，成交量超过1540万股，为平均水平的逾两倍，其52周价格区间为0.23美元至1.35美元 [7] Aquestive Therapeutics, Inc (AQST) - 公司股价在盘后交易中上涨11.41%至5.86美元，主要受其口服肾上腺素候选药物Anaphylm的监管进展推动，FDA确认无需咨询委员会会议即可审查其新药申请 [8] - 该股在常规交易时段收于5.26美元，下跌2.95%，成交量超过360万股，接近日均水平的两倍，其52周价格区间为2.12美元至6.00美元 [9] Ovid Therapeutics Inc (OVID) - 公司股价在盘后交易中上涨4.26%至1.47美元，该股在常规交易时段触及52周新高，市场持续关注其针对耐药性癫痫的神经疾病候选药物管线 [10] - 该股在常规交易时段收于1.41美元，上涨0.71%，成交量超过240万股，略高于平均水平，其52周价格区间为0.2430美元至1.47美元 [11]

Aquestive Therapeutics (AQST) shares rallied 14.8% in the last trading session to close at $5.67. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 26.3% gain over the past four weeks.The surge in stock price is likely due to positive expectations from investors regarding Aquestive’s regulatory filing, which seeks FDA approval for its key product candidate, Anaphylm, to treat severe allergic reactions. Earlier ...

公司核心观点 - 股票在过去几年重获新生 股价回升至中等个位数水平 [1] - 股价上涨主要得益于市场对其口服EpiPen替代药物Anaphylm的日益增长的热情 [1] - 若Anaphylm在未来几个月内获得FDA批准 公司股价预计将大幅飙升 [1] - 当前投资情境具有二元性 完全取决于Anaphylm能否获得FDA批准 [1] 公司业务与产品管线 - 公司致力于开发和商业化基于口服与舌下薄膜的药物 [2] - 产品针对的适应症包括癫痫 阿片类药物依赖 帕金森病 注意力缺陷多动障碍以及严重过敏反应 [2] - 公司推进专有药物递送平台 主要专注于中枢神经系统和紧急治疗领域 [2]

U.S. stocks were higher, with the Nasdaq Composite gaining more than 100 points on Friday.Shares of CoreWeave, Inc. CRWV rose sharply during Friday's session after Loop Capital initiated coverage with a Buy rating and announced a $165 price target.CoreWeave shares jumped 4.8% to $127.15 on Friday.Here are some other big stocks recording gains in today’s session.Quantum Computing Inc. QUBT shares jumped 22.5% to $22.47.WhiteFiber, Inc. WYFI gained 17.6% to $27.53. Roth Capital analyst Darren Aftahi, on Thurs ...

核心观点 - 多只小盘股在盘后交易中延续涨势 主要受战略更新 领导层变动和研发进展推动 [1] Adaptimmune Therapeutics (ADAP) - 盘后交易股价飙升30%至0202美元 此前交易日涨幅达98% 成交量705百万股远超日均60百万股 [2] - 第二季度净亏损3030万美元 每股亏损002美元 总收入1370万美元 其中TECELRA产品销售额1110万美元 环比增长超150% [3] - 8月将细胞疗法资产以5500万美元首付款加最高3000万美元里程碑付款出售给US WorldMeds 公司已偿还债务并重组聚焦PRAME和CD70疗法 [4] Butterfly Network (BFLY) - 盘后上涨1058%至209美元 日内涨幅1595% 成交量12百万股达日均三倍 [4] - 入选TIME 2025全球健康科技顶级公司名单 体现AI超声成像创新实力 新任首席技术官Victor Ku上任强化技术布局 [5] - JAMA研究证实其床旁超声方案显著缩短住院时间并降低成本 临床价值获验证 [5] Aquestive Therapeutics (AQST) - 盘后上涨769%至532美元 年内累计涨幅近39% 交易接近52周高点580美元 [6] - FDA确认无需咨询委员会审查Anaphylm舌下膜剂新药申请 审批流程简化 PDUFA日期定于2026年1月 [7] - 近期获得7500万美元战略资金支持 为Anaphylm潜在上市做准备 [7] ALX Oncology Holdings (ALXO) - 盘后上涨917%至119美元 日内涨幅381% [8] - 首席执行官Jason Lettmann于9月17日增持92,233股 总持股超305,000股 显示管理层信心 [9] - 核心候选药Evorpacept与Jazz Pharmaceuticals、MD Anderson癌症中心和赛诺菲合作 开展多项胃癌、泌尿系及头颈癌的I/II期试验 [10] Ekso Bionics Holdings (EKSO) - 盘后上涨537%至451美元 日内涨幅974% 交易于52周区间273-1905美元中位 [10] - 今年入选英伟达连接计划 推动AI与可穿戴外骨骼技术融合 近期推出Virtual eksoUniversity平台加强物理治疗师继续教育 [11] CEL-SCI Corp (CVM) - 盘后上涨527%至939美元 日内涨幅102% [12] - 完成1000万美元公开发行以支持临床及注册工作 在沙特申请突破性药物认定用于头颈癌治疗药物Multikine 若获批可在60天内实现患者准入 [13] - 首席执行官Geert Kersten以每股685美元均价增持29,197股 持股比例增加6691% [13]

Aquestive Therapeutics (NasdaqGM:AQST) FY Conference September 08, 2025 10:00 AM ET Company ParticipantsDaniel Smith - Equity Research AssociateDaniel Barber - CEO, President & DirectorSherry Korczynski - CCOConference Call ParticipantsNone - AnalystDaniel SmithMorning everyone, and thank you for joining Day One of the HC Wainwright 27th Annual Global Investment Conference 2025. My name is Daniel Smith, and I'm an HC Wainwright Equity Research Associate in Biotechnology. With that said, let me introduce our ...